Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
Cash & Cash Equivalents
Glenmark Life Sciences Ltd
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
Cash & Cash Equivalents
₹2.8B
|
CAGR 3-Years
35%
|
CAGR 5-Years
168%
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash & Cash Equivalents
₹7.1B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Cash & Cash Equivalents
₹8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
17%
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash & Cash Equivalents
₹72.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cash & Cash Equivalents
₹11.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash & Cash Equivalents
₹5.6B
|
CAGR 3-Years
6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-4%
|
See Also
What is Glenmark Life Sciences Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.8B
INR
Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Cash & Cash Equivalents amounts to 2.8B INR.
What is Glenmark Life Sciences Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
168%
Over the last year, the Cash & Cash Equivalents growth was 0%. The average annual Cash & Cash Equivalents growth rates for Glenmark Life Sciences Ltd have been 35% over the past three years , 168% over the past five years .